e=1-

/rvaccine efficiency and expectation of N+M, respectively, when r is the vaccine-to-placebo ratio of person-times at risk, ie the ratio of the numbers of participants in each group. Reparameterisation such that the likelihood factorises into a function of e and a function of another approach to infer about e while treating as a nuisance parameter is to condition on N+M). The paper then proposes as an application of this remark an analysis of the results of three SARS-Cov-2 vaccines, meaning using the pairs (N,M) for each vaccine and deriving credible intervals, which sounds more like an exercise in basic Bayesian inference than a fundamental step in assessing the efficiency of the vaccines…

. Using a product prior for this parameterisation leads to a posterior on e times a posterior on . This is a nice remark, which may have been made earlier (as for instance